Results 51 to 60 of about 2,121 (171)

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Pharmaceuticals, 2021
There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD).
Rene Zeiss, Maximilian Gahr, Heiko Graf
doaj   +1 more source

Transdiagnostic and symptom‐domain associations between mental illnesses and future self‐connectedness versus future self‐valence

JCPP Advances, EarlyView.
Abstract Background Future time perspective dimensions have been linked to various mental illnesses. Given the tendency for mental illnesses to co‐occur, it is necessary to disentangle associations between future‐oriented constructs and shared versus symptom‐domain‐specific psychopathology.
Yi Yang, Ingrid Obsuth, Jean‐Louis van Gelder, Denis Ribeaud, Manuel Eisner, Xinxin Zhu, Aja Louise Murray   +6 more
wiley   +1 more source

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold ...
Stefano Damiani, Marika Orlandi, Umberto Provenzani, Elisa Bortolin, Margherita Rovida, Riccardo Stefanelli, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Ricardo E. Carrion, Rolando I. Castillo‐Passi, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Barbara A. Cornblatt, Covadonga M. Diaz‐Caneja, Lauren M. Ellman, Abigayle Fogarty, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung‐Wan Kim, Nikolaos Koutsouleris, Zsuliet Kristof, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Josh Nguyen, Merete Nordentoft, Godfrey D. Pearlson, Nora Penzel, Jesus Perez, Diana O. Perkins, Albert R. Powers III, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Cassandra Wannan, Jijun Wang, Heather Wastler, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Cheryl M. Corcoran, Tina Kapur, Ofer Pasternak, Carrie E. Bearden, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Barnaby Nelson, Martha E. Shenton, Scott W. Woods, Paolo Fusar‐Poli   +73 more
wiley   +1 more source

In Silico Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 Receptor

Frontiers in Immunology, 2022
Various metabolites identified with therapeutic mushrooms have been found from different sources and are known to have antibacterial, antiviral, and anticancer properties.
Faez Iqbal Khan, Fakhrul Hassan, Dakun Lai   +2 more
doaj   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats

Frontiers in Neuroscience, 2023
IntroductionPsilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT2A receptors, it has high binding affinity also to 5 ...
Filip Tylš, Filip Tylš, Čestmír Vejmola, Čestmír Vejmola, Vlastimil Koudelka, Václava Piorecká, Václava Piorecká, Lukáš Kadeřábek, Marcel Bochin, Marcel Bochin, Tomáš Novák, Tomáš Novák, Martin Kuchař, Martin Kuchař, Zdeňka Bendová, Martin Brunovský, Martin Brunovský, Jiří Horáček, Jiří Horáček, Tomáš Pálení ček, Tomáš Pálení ček   +20 more
doaj   +1 more source

A source-preserving living dataset of psilocybin and psilocin publications, preprints, and trial records

Christopher B. Germann
  +7 more sources

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Pharmacokinetics of Psilocybin: A Systematic Review

Pharmaceutics
Background: Psilocybin has shown promise in therapeutic applications for mental disorders. Understanding the pharmacokinetics of psilocybin and its active metabolite psilocin is crucial for optimizing its clinical use and minimizing adverse effects ...
Shakila Meshkat, Huda Al-Shamali, Argyrios Perivolaris, Trusha Tullu, Richard J. Zeifman, Yanbo Zhang, Lisa Burback, Olga Winkler, Andrew Greenshaw, Muhammad Ishrat Husain, Amy C. Reichelt, Eric Vermetten, Manish K. Jha, Rakesh Jetly, Raimar Loebenberg, Venkat Bhat   +15 more
doaj   +1 more source